Recent 8-K filings for LUNG

• April 29, 2026, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M

  Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).

• March 5, 2026, 6:59 PM ET debt materiality 0.70 neutral item 1.01item 1.02item 2.03item 3.02item 9.01 ◈ Debt Financings◈ Material Agreements

  Pulmonx enters $60M secured credit facility with Perceptive; draws $40M upfront

  $60M senior secured term loan from Perceptive; $40M drawn at closing, up to $20M additional tranches tied to $92.5M and $100M revenue milestones.

• March 4, 2026, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Pulmonx Q4 revenue declines 5% YoY; full year up 8%; guides flat FY2026 revenue $90-92M

  Q4 2025 revenue $22.6M, down 5% YoY (down 7% constant currency); US revenue fell 11% to $14.1M.

• November 12, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Pulmonx Q3 rev $21.5M (+5%), net loss $14.0M; guides FY rev $89-90M; adds COO role

  Worldwide revenue $21.5M (+5% YoY); US $14.0M (+1%), Intl $7.5M (+15%).

• October 27, 2025, 7:59 PM ET leadership materiality 0.85 negative item 2.02item 5.02item 9.01

  Pulmonx reappoints Glen French as CEO and Derrick Sung as COO/CFO; Q3 preliminary revenue ~$21.5M

  Glen French (former CEO 2014-2024) reappointed President and CEO; Derrick Sung (former CFO) appointed COO and CFO effective Nov 3, 2025.

• July 30, 2025, 7:59 PM ET earnings materiality 0.78 negative item 2.02item 9.01

  Pulmonx Q2 revenue up 15% to $23.9M but cuts FY2025 guidance to $90-92M

  Revenue $23.9M (+15% YoY); U.S. $14.7M (+6%), International $9.1M (+32% constant currency +27%).

• May 23, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Pulmonx stockholders reelect three directors; say-on-pay passes by slim margin

  All three Class II nominees elected: Ferrari (16.97M for, 11.95M withheld), Florin, Williamson.

• April 30, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Pulmonx Q1 2025 revenue $22.5M (+20% YoY); net loss $14.4M; reaffirms FY guidance

  Worldwide revenue of $22.5M, up 20% YoY (21% constant currency); U.S. $14.2M (+11%), international $8.3M (+39%).

• February 19, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Pulmonx reports record Q4 revenue $23.8M (+23% YoY) and FY2024 revenue $83.8M (+22%); FY2025 guidance $96-98M

  Record Q4 2024 worldwide revenue $23.8M, up 23% YoY; U.S. revenue $15.9M (+16%), international $7.9M (+42%).

• October 30, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Pulmonx Q3 2024 revenue $20.4M (+15% YoY), net loss $14.1M

  Worldwide revenue $20.4M, up 15% YoY; U.S. revenue $13.8M (+17% YoY); international $6.6M (+12%).

• July 31, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M

  Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).

• May 23, 2024, 7:59 PM ET other material materiality 0.50 neutral item 1.01item 9.01

  Pulmonx extends and expands headquarters lease through 2035, adds 25,254 sq ft

  Extended lease for 24,591 sq ft at 700 Chesapeake Dr to July 31, 2035; monthly base rent starts at $113,118.60 Aug 2025.

• May 17, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

  Pulmonx annual meeting elects directors; say-on-pay passes with narrow margin

  Glendon E. French re-elected with 16.9M for vs 13.7M withheld; Tiffany Sullivan with 16.7M for vs 13.9M withheld.

• May 1, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Pulmonx Q1 revenue $18.9M (+30% YoY); net loss narrows to $13.7M

  Q1 revenue $18.9M, up 30% YoY (29% constant currency); U.S. revenue $12.9M (+38%).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.68 · Most common event earnings

4 positive 3 negative 7 neutral

source · LUNG on sec.gov